Evaluating the Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube
Human immunodeficiency virus (HIV) viral suppression was evaluated after receipt of crushed or dissolved bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered via enteral tube during hospitalization. Eighty-nine percent of patients (17/19) were virally suppressed (<200 copies/mL) within 1 year of receiving B/F/TAF via tube, suggesting that administration via tube is a reasonable alternative to changing antiretroviral regimens.
Authors
- Suzanne M. McCluskey (ORCID: https://orcid.org/0000-0001-8463-5430)
- Alexander E Rock (ORCID: https://orcid.org/0000-0002-2067-4673)
- Jeffrey C Pearson (ORCID: https://orcid.org/0000-0002-5276-1050)
- Eric M Gillett (ORCID: https://orcid.org/0000-0001-9528-8526)
- Joshua Mercure
- Kayla Bey
Institutions
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1093/ofid/ofaf588
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40